Scholarlink

<p>PROteolysis TArgeting Chimeras (PROTACs) are bifunctional molecules that offer a novel approach to targeted protein degradation, showing particular promise for previously ‘undruggable’ targets. Despite their therapeutic potential, significant challenges remain in optimizing the pharmacokinetic (PK) properties of PROTACs, particularly in terms of their ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity) characteristics. In this study, we drew on the experience of previous work and combined traditional machine learning with multiple molecular fingerprints to propose a PROTAC pharmacokinetic property prediction model EGFR-PROPK. We conducted in-vivo experiments on 100 EGFR-targeting PROTAC molecules, focusing on clearance (CL), half-life (T<sub>1/2</sub>), and apparent volume of distribution (Vss), which are the most intuitive and commonly used macro parameters to describe the PK properties of a drug since they describe the absorption-distribution-elimination process of drugs in the body from different perspectives. Our findings reveal that traditional models trained on small molecules perform poorly on PROTACs. However, training the models on PROTAC-specific data significantly improved prediction accuracy, achieving correlation coefficients of 0.78, 0.75, and 0.52 between the predicted and observed values for T<sub>1/2,</sub> CL and Vss, respectively, highlighting the need for tailored approaches in PK evaluation for these unique molecules. These insights are critical for advancing the design and development of PROTAC-based therapies.</p><p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

A machine learning-based pharmacokinetics predictor (EGFR-PROPK) for EGFR-targeting PROTACs

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年2月16日

查看全文
  • Ran Zhang,
  • Fenglei Li,
  • Yao Liu,
  • Ya Geng,
  • Yongqi Zhou,
  • Li Zeng,
  • Fang Bai

摘要

PROteolysis TArgeting Chimeras (PROTACs) are bifunctional molecules that offer a novel approach to targeted protein degradation, showing particular promise for previously ‘undruggable’ targets. Despite their therapeutic potential, significant challenges remain in optimizing the pharmacokinetic (PK) properties of PROTACs, particularly in terms of their ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity) characteristics. In this study, we drew on the experience of previous work and combined traditional machine learning with multiple molecular fingerprints to propose a PROTAC pharmacokinetic property prediction model EGFR-PROPK. We conducted in-vivo experiments on 100 EGFR-targeting PROTAC molecules, focusing on clearance (CL), half-life (T1/2), and apparent volume of distribution (Vss), which are the most intuitive and commonly used macro parameters to describe the PK properties of a drug since they describe the absorption-distribution-elimination process of drugs in the body from different perspectives. Our findings reveal that traditional models trained on small molecules perform poorly on PROTACs. However, training the models on PROTAC-specific data significantly improved prediction accuracy, achieving correlation coefficients of 0.78, 0.75, and 0.52 between the predicted and observed values for T1/2, CL and Vss, respectively, highlighting the need for tailored approaches in PK evaluation for these unique molecules. These insights are critical for advancing the design and development of PROTAC-based therapies.